Evaluation of Radium-223 Dichloride in the Treatment of Castration-Resistant Prostate Adenocarcinoma with Symptomatic Bone Metastases

被引：0
|
作者：
Maestre-Cutillas, R. [1 ]
Sanchez-Tornero, A. M. [2 ]
Baz-Sanz, L. [1 ]
Rubio-Fernandez, G. [1 ]
Casas-Fernandez, L. [2 ]
Romero-Otero, M. [2 ]
Perez-Iruela, J. A. [1 ]
机构：
[1] Hosp Univ Ramon Y Cajal, Madrid, Spain
[2] Hosp Clin Univ Valencia, Valencia, Spain
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2023年 / 50卷 / SUPPL 1期
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
EP-0559
引用
收藏
页码：S652 / S652
页数：1
相关论文
共 50 条
  • [31] Integration of radium-223 dichloride (Xofigo) into clinical practice for the treatment of castration-resistant prostate cancer.
    Doyle, Catherine Mary
    Mills, Matthew
    Damgaci, Sultan
    Smith, Johnna
    Zhang, Jingsong
    Fishman, Mayer N.
    El-Haddad, Ghassan
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [32] Impact of treatment delay in Radium-223 Dichloride therapy of metastatic castration-resistant prostate cancer patients
    Fosbol, M. O.
    Holm, S.
    Petersen, P. M.
    Daugaard, G.
    Mortensen, J.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2016, 43 : S214 - S214
  • [33] Radium-223 Is the Preferred Therapy in Bone-Predominant Symptomatic Metastatic Castration-Resistant Prostate Cancer
    Dreicer, Robert
    Li, Jing
    Andrew, J.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2015, 13 (05) : 293 - +
  • [34] Safety and efficacy of radium-223 dichloride (BAY 88-8223) in Japanese patients with castration-resistant prostate cancer and bone metastases
    Uemura, Hirotsugu
    Uemura, Hiroji
    Matsubara, N.
    Kaneko, M.
    Doi, T.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S489 - S489
  • [35] Retrospective analysis of radium-223 treatment for adults with progressive castration-resistant metastatic prostate cancer with symptomatic bone metastasis
    Gaffney, J.
    O'Boyle, G.
    Gaffney, B.
    Roshan, D.
    Sullivan, F.
    Ibrahim, N.
    Martin, J.
    Small, C.
    EUROPEAN JOURNAL OF CANCER, 2017, 72 : S194 - S194
  • [36] Combination radium-223 therapies in patients with bone metastases from castration-resistant prostate cancer: A review
    Cursano, M. C.
    Iuliani, M.
    Casadei, C.
    Stellato, M.
    Tonini, G.
    Paganelli, G.
    Santini, D.
    De Giorgi, U.
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2020, 146
  • [37] RADIUM RA 223 DICHLORIDE IN CASTRATION-RESISTANT PROSTATE CANCER
    Joung, J. Y.
    Ha, Y-S.
    Kim, I. Y.
    DRUGS OF TODAY, 2013, 49 (08) : 483 - 490
  • [38] Single-center experience with radium-223 in patients with castration-resistant prostate cancer and bone metastases
    Kapoor, Anil
    Wong, Nathan C.
    Wang, Yuding
    Mukherjee, Som
    Hotte, Sebastien
    Dayes, Ian
    Lukka, Himu
    ASIAN JOURNAL OF ANDROLOGY, 2020, 22 (04) : 437 - 438
  • [39] Three-year Safety of Radium-223 Dichloride in Patients with Castration-resistant Prostate Cancer and Symptomatic Bone Metastases from Phase 3 Randomized Alpharadin in Symptomatic Prostate Cancer Trial
    Parker, Christopher C.
    Coleman, Robert E.
    Sartor, Oliver
    Vogelzang, Nicholas J.
    Bottomley, David
    Heinrich, Daniel
    Helle, Svein I.
    O'Sullivan, Joe M.
    Fossa, Sophie D.
    Chodacki, Ales
    Wiechno, Pawel
    Logue, John
    Seke, Mihalj
    Widmark, Anders
    Johannessen, Dag Clement
    Hoskin, Peter
    James, Nicholas D.
    Solberg, Arne
    Syndikus, Isabel
    Kliment, Jan
    Wedel, Steffen
    Boehmer, Sibylle
    Dall'Oglio, Marcos
    Franzen, Lars
    Bruland, Oyvind S.
    Petrenciuc, Oana
    Staudacher, Karin
    Li, Rui
    Nilsson, Sten
    EUROPEAN UROLOGY, 2018, 73 (03) : 427 - 435
  • [40] The Timing of Radium-223 Therapy in Castration-Resistant Prostate Cancer
    Sartor, Oliver
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2015, 13 (09) : 570 - 572
12345